Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study
Author(s) -
Mariasanta Napolitano,
Giorgia Saccullo,
Alessandra Malato,
Delia Sprini,
Walter Ageno,
Davide Imberti,
Doris Mascheroni,
Eugenio Bucherini,
Pina Gallucci,
A. D’Alessio,
T Prantera,
P. Spadaro,
Stefano Rotondo,
Pierpaolo Di Micco,
Vincenzo Oriana,
O Urbano,
F. Recchia,
Angelo Ghirarduzzi,
Lucio Lo Coco,
Salvatrice Mancuso,
Alessandra Casuccio,
Giovam Battista Rini,
Sergio Siragusa
Publication year - 2014
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2013.51.7433
Subject(s) - medicine , dacus , deep vein , thrombosis , cancer , heparin , surgery , oncology , tephritidae , marketing , pest analysis , business
We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom